A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

December 31, 2025

Conditions

Aplastic Anemia

Interventions

DRUG

Romiplostim

Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT06535685 - A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA | Biotech Hunter | Biotech Hunter